EVALUATION OF OVERALL SURVIVAL (OS) AND DISEASE-FREE SURVIVAL (DFS) IN PATIENTS SUBMITTED TO NEOADJUVANT CHEMOTHERAPY AND ITS RELATION WITH THE ANATOMOPATHOLOGICAL RESPONSE.

INABA, L. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), BASTOS, E. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), RODRIGUES, F. F. O. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), SILVA, R. M. (Instituto do Câncer Dr. Arnaldo

Instituto do Câncer Dr. Arnaldo Vieira de Carvalho (ICAVC)To evaluate the importance of pathological complete response (pCR) as a predictor of overall survival (OS) and disease-free survival (DFS) in the neoadjuvant chemotherapy scenario. A retrospective database analysis from our service in patients with breast cancer treated at our institution (ICAVC) during 08/31/2006 and 01/10/2010 with follow up until 01/12/2016. A total of 106 patients with invasive breast cancer were included in the study, and 32 (30,2%) received neoadjuvant chemotherapy based on anthracycline and taxane. We observed that five (15.6%) patients presented pCR (defined as the absence of invasive neoplasia in the breast and axilla) and 27 (84%) presented residual disease in surgical specimens as a result of the final anatomopathological analysis. When we analyzed the Kaplan-Meier curves of our cohort, we notice that patients submitted to neoadjuvant chemotherapy with pCR had an OS and DFS larger than the group without anatomopathological response, but there was no statistical difference between the groups. In the scenario of neoadjuvant chemotherapy, patients with pCR had evidence that suggests a better OS and DFS when compared to the group with an absence of pCR.breast cancer, neoadjuvant chemotherapy, overall survival, pathologic complete response

Return